- Home
- FLIC vs IMMP Comparison
FLIC vs IMMP Comparison
Compare FLIC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLIC
- IMMP
- Stock Information
- Founded
- FLIC 1927
- IMMP 1987
- Country
- FLIC United States
- IMMP Australia
- Employees
- FLIC N/A
- IMMP N/A
- Industry
- FLIC Major Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- FLIC Finance
- IMMP Health Care
- Exchange
- FLIC Nasdaq
- IMMP Nasdaq
- Market Cap
- FLIC 246.0M
- IMMP 211.1M
- IPO Year
- FLIC N/A
- IMMP N/A
- Fundamental
- Price
- FLIC $12.39
- IMMP $1.86
- Analyst Decision
- FLIC Buy
- IMMP Buy
- Analyst Count
- FLIC 1
- IMMP 2
- Target Price
- FLIC $16.56
- IMMP $8.50
- AVG Volume (30 Days)
- FLIC 64.1K
- IMMP 648.0K
- Earning Date
- FLIC 04-30-2025
- IMMP 05-16-2025
- Dividend Yield
- FLIC 6.86%
- IMMP N/A
- EPS Growth
- FLIC N/A
- IMMP N/A
- EPS
- FLIC 0.72
- IMMP N/A
- Revenue
- FLIC $85,364,000.00
- IMMP $3,019,249.00
- Revenue This Year
- FLIC $18.14
- IMMP $11.25
- Revenue Next Year
- FLIC N/A
- IMMP $10.22
- P/E Ratio
- FLIC $16.72
- IMMP N/A
- Revenue Growth
- FLIC N/A
- IMMP 24.11
- 52 Week Low
- FLIC $9.30
- IMMP $1.32
- 52 Week High
- FLIC $15.03
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- FLIC 62.39
- IMMP 53.43
- Support Level
- FLIC $11.92
- IMMP $1.44
- Resistance Level
- FLIC $12.33
- IMMP $2.71
- Average True Range (ATR)
- FLIC 0.32
- IMMP 0.17
- MACD
- FLIC 0.14
- IMMP 0.05
- Stochastic Oscillator
- FLIC 92.13
- IMMP 29.75
About FLIC First of Long Island Corporation (The)
First of Long Island Corp is a holding company that provides financial services. It offers services of saving accounts, current accounts, and capital gain accounts. The company also provides lending services, such as commercial and residential mortgage loans, industrial loans, small business credit scored loans, and other credit facilities. In addition, the company provides account reconciliation services, ATM Banking, bill payment, cash management services, mobile banking, online banking, and payroll services to privately owned businesses, professionals, consumers, and public bodies.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.